期刊文献+

NHT后血清IL-6对前列腺癌RP病人预后影响

THE VALUE OF SERUM IL-6 LEVEL AFTER NEOADJUVANT HORMONAL THERAPY IN PREDICTING THE PROGNOSIS OF PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY
下载PDF
导出
摘要 目的探讨新辅助内分泌治疗(NHT)后血清白细胞介素-6(IL-6)水平在预测前列腺癌根治性前列腺切除术(RP)后生化复发中的价值。方法收集接受NHT后行RP的294例前列腺癌病人的临床及病理资料,所有病人术前均使用酶联免疫吸附法检测血清IL-6浓度,按其中位数值分为高水平组和低水平组,比较两组间临床病理特征的差别,应用Kaplan-Meier生存分析方法、Cox比例风险模型分析NHT后IL-6水平对病人预后的影响。结果高水平组和低水平组间年龄、体质量指数、吸烟、高血压、糖尿病、切缘阳性、精囊侵犯及穿刺Gleason评分差异无统计学意义(P>0.05);与IL-6低水平组相比,高水平组包膜侵犯率、淋巴结阳性率、T分期、前列腺特异性抗原(PSA)水平均显著升高(χ^(2)=3.890~13.397,P<0.01)。Kaplan-Meier生存分析显示,IL-6高水平组病人生化复发的概率明显高于低水平组(χ^(2)=6.404,P<0.05)。多因素Cox比例风险回归模型分析显示,血IL-6水平(HR=1.531,95%CI=1.011~2.318,P<0.05)、淋巴结转移(HR=1.818,95%CI=1.093~3.025,P<0.05)、T分期(HR=1.769,95%CI=1.132~2.762,P<0.05)、PSA≥20μg/L(HR=3.108,95%CI=1.421~6.799,P<0.05)是影响术后生化复发的独立危险因素。结论接受NHT后前列腺癌病人血清IL-6水平可协助预测RP术后生化复发,有助于临床决策的选择。 Objective To study the value of serum interleukin-6(IL-6)level after neoadjuvant hormonal therapy(NHT)in predicting biochemical recurrence after radical prostatectomy(RP).Methods The clinicopathological data of 294 patients with prostate cancer who underwent RP after NHT were collected.Enzyme-linked immunosorbent assay was used to measure the preoperative serum IL-6 concentration of the patients.According to the median concentration of IL-6,the patients were divided into high-level group and low-level group for comparison of clinicopathological characteristics.The impact of post-NHT IL-6 level on prognosis was analyzed using Kaplan-Meier survival analysis and Cox proportional risk model.Results There were no significant differences between the two groups in terms of age,body mass index,smoking,hypertension,diabetes,positive margin,seminal vesicle invasion,and Gleason scores(P>0.05).Compared with the low-level group,the high-level group showed significantly increased capsule invasion rate,positive rate of lymph node,T staging,and prostate specific antigen level(χ^(2)=3.890-13.397,P<0.01).According to the Kaplan-Meier survival analysis,the probability of biochemical recurrence was significantly higher in the high-level group than in the low-level group(χ^(2)=6.404,P<0.05).A multivariate Cox proportional risk regression model was used to identify the independent risk factors for postoperative biochemical recurrence,including IL-6 level(HR=1.531,95%CI=1.011-2.318,P<0.05),lymph node metastasis(HR=1.818,95%CI=1.093-3.025,P<0.05),T staging(HR=1.769,95%CI=1.132-2.762,P<0.05),and PSA≥20μg/L(HR=3.108,95%CI=1.421-6.799,P<0.05).Conclusion Serum IL-6 level after NHT can be useful in predicting biochemical recurrence after RP and making informed clinical decisions.
作者 刘锋 姚榆 刘帅 朱耀 张桂铭 LIU Feng;YAO Yu;LIU Shuai;ZHU Yao;ZHANG Guiming(Department of Urology,The Affiliated Hospital of Qingdao University,Qingdao 266003,China)
出处 《青岛大学学报(医学版)》 CAS 2023年第1期127-130,共4页 Journal of Qingdao University(Medical Sciences)
基金 青岛市医药卫生科研计划项目(2021-WJZD170)。
关键词 前列腺肿瘤 白细胞介素6 前列腺切除术 预后 prostatic neoplasms interleukin-6 prostatectomy prognosis
  • 相关文献

参考文献4

二级参考文献29

  • 1贺荣芳,胡忠良,沈明,文继舫.胃癌组织中PTEN,VEGF,MMP-9的表达及相关性研究[J].中国普通外科杂志,2005,14(3):173-177. 被引量:39
  • 2廖新红.经直肠超声检测在前列腺增生症及前列腺癌诊断中的应用[J].广西医科大学学报,2010,27(6):969-971. 被引量:3
  • 3叶定伟,李长岭.前列腺癌发病趋势的回顾和展望[J].中国癌症杂志,2007,17(3):177-180. 被引量:118
  • 4李鸣,那彦群.不同水平前列腺特异抗原的前列腺癌诊断率[J].中华医学杂志,2008,88(1):16-18. 被引量:56
  • 5Siegel R L, Miller K D, Jemal A. Cancer statistics, 2015 [ J]. CA Cancer J Clin, 2015, 65( 1 ) : 5 -29.
  • 6Chai E Z, Siveen K S, Shanmugam M K, et al. Analysis of the intricate relationship between chronic inflammation and cancer [J]. Biochem, 2015, 468(1): 1-15.
  • 7Sheng W H, Chiang B L, Chang S C, et al. Clinical manifesta- tions and inflammatory cytokine responses in patients with severe acute respiralory syndrome[J]. J Formos Med Assoc, 2005, 104 (10) : 715 -23.
  • 8Ara T, Declerck Y A. Interleukin-6 in bone metastasis and cancer progression[J]. Eur J Cancer, 2010, 46(7) : 1223 -31.
  • 9Zoubeidi A, Rocha J, Zouanat F Z, et al. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and acti- vator of transcription 3 and promote human prostate cancer cell growth[J]. MolCancerRes, 2009, 7(1): 142 -55.
  • 10Lee S O, Chun J Y, Nadiminty N, et al. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine dif- ferentiation to stimulator accompanied by androgen receptor activa- tion during LNCaP prostate cancer cell progression[ J]. Prostate, 2007, 67(7) : 764 -73.

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部